BACKGROUND: We sought to describe the antemortem clinical and neuroimaging features among patients with frontotemporal lobar degeneration with TDP-43 immunoreactive inclusions (FTLD-TDP). METHODS: Subjects were recruited from a consecutive series of patients with a primary neuropathologic diagnosis of FTLD-TDP and antemortem MRI. Twenty-eight patients met entry criteria: 9 with type 1, 5 with type 2, and 10 with type 3 FTLD-TDP. Four patients had too sparse FTLD-TDP pathology to be subtyped. Clinical, neuropsychological, and neuroimaging features of these cases were reviewed. Voxel-based morphometry was used to assess regional gray matter atrophy in relation to a group of 50 cognitively normal control subjects. RESULTS: Clinical diagnosis varied between the groups: semantic dementia was only associated with type 1 pathology, whereas progressive nonfluent aphasia and corticobasal syndrome were only associated with type 3. Behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease were seen in type 2 or type 3 pathology. The neuroimaging analysis revealed distinct patterns of atrophy between the pathologic subtypes: type 1 was associated with asymmetric anterior temporal lobe atrophy (either left- or right-predominant) with involvement also of the orbitofrontal lobes and insulae; type 2 with relatively symmetric atrophy of the medial temporal, medial prefrontal, and orbitofrontal-insular cortices; and type 3 with asymmetric atrophy (either left- or right-predominant) involving more dorsal areas including frontal, temporal, and inferior parietal cortices as well as striatum and thalamus. No significant atrophy was seen among patients with too sparse pathology to be subtyped. CONCLUSIONS: FTLD-TDP subtypes have distinct clinical and neuroimaging features, highlighting the relevance of FTLD-TDP subtyping to clinicopathologic correlation.
BACKGROUND: We sought to describe the antemortem clinical and neuroimaging features among patients with frontotemporal lobar degeneration with TDP-43 immunoreactive inclusions (FTLD-TDP). METHODS: Subjects were recruited from a consecutive series of patients with a primary neuropathologic diagnosis of FTLD-TDP and antemortem MRI. Twenty-eight patients met entry criteria: 9 with type 1, 5 with type 2, and 10 with type 3 FTLD-TDP. Four patients had too sparse FTLD-TDP pathology to be subtyped. Clinical, neuropsychological, and neuroimaging features of these cases were reviewed. Voxel-based morphometry was used to assess regional gray matter atrophy in relation to a group of 50 cognitively normal control subjects. RESULTS: Clinical diagnosis varied between the groups: semantic dementia was only associated with type 1 pathology, whereas progressive nonfluent aphasia and corticobasal syndrome were only associated with type 3. Behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease were seen in type 2 or type 3 pathology. The neuroimaging analysis revealed distinct patterns of atrophy between the pathologic subtypes: type 1 was associated with asymmetric anterior temporal lobe atrophy (either left- or right-predominant) with involvement also of the orbitofrontal lobes and insulae; type 2 with relatively symmetric atrophy of the medial temporal, medial prefrontal, and orbitofrontal-insular cortices; and type 3 with asymmetric atrophy (either left- or right-predominant) involving more dorsal areas including frontal, temporal, and inferior parietal cortices as well as striatum and thalamus. No significant atrophy was seen among patients with too sparse pathology to be subtyped. CONCLUSIONS:FTLD-TDP subtypes have distinct clinical and neuroimaging features, highlighting the relevance of FTLD-TDP subtyping to clinicopathologic correlation.
Authors: S M Brambati; K P Rankin; J Narvid; W W Seeley; D Dean; H J Rosen; B L Miller; J Ashburner; M L Gorno-Tempini Journal: Neurobiol Aging Date: 2007-07-02 Impact factor: 4.673
Authors: G D Rabinovici; W W Seeley; E J Kim; M L Gorno-Tempini; K Rascovsky; T A Pagliaro; S C Allison; C Halabi; J H Kramer; J K Johnson; M W Weiner; M S Forman; J Q Trojanowski; S J Dearmond; B L Miller; H J Rosen Journal: Am J Alzheimers Dis Other Demen Date: 2007 Dec-2008 Jan Impact factor: 2.035
Authors: Murray Grossman; Elisabeth M Wood; Peachie Moore; Manuela Neumann; Linda Kwong; Mark S Forman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Virginia M-Y Lee; John Q Trojanowski Journal: Arch Neurol Date: 2007-10
Authors: Vivianna M Van Deerlin; Elisabeth McCarty Wood; Peachie Moore; Wuxing Yuan; Mark S Forman; Christopher M Clark; Manuela Neumann; Linda K Kwong; John Q Trojanowski; Virginia M-Y Lee; Murray Grossman Journal: Arch Neurol Date: 2007-08
Authors: S Davion; N Johnson; S Weintraub; M-M Mesulam; A Engberg; M Mishra; M Baker; J Adamson; M Hutton; R Rademakers; E H Bigio Journal: Neurology Date: 2007-05-23 Impact factor: 9.910
Authors: John R Hodges; Jo Mitchell; Kate Dawson; Maria Grazia Spillantini; John H Xuereb; Paul McMonagle; Peter J Nestor; Karalyn Patterson Journal: Brain Date: 2009-10-05 Impact factor: 13.501
Authors: Jonathan D Rohrer; Gerard R Ridgway; Sebastian J Crutch; Julia Hailstone; Johanna C Goll; Matthew J Clarkson; Simon Mead; Jonathan Beck; Cath Mummery; Sebastien Ourselin; Elizabeth K Warrington; Martin N Rossor; Jason D Warren Journal: Neuroimage Date: 2009-08-11 Impact factor: 6.556
Authors: Jonathan Beck; Jonathan D Rohrer; Tracy Campbell; Adrian Isaacs; Karen E Morrison; Emily F Goodall; Elizabeth K Warrington; John Stevens; Tamas Revesz; Janice Holton; Safa Al-Sarraj; Andrew King; Rachael Scahill; Jason D Warren; Nick C Fox; Martin N Rossor; John Collinge; Simon Mead Journal: Brain Date: 2008-01-29 Impact factor: 13.501
Authors: Ian R A Mackenzie; Matt Baker; Stuart Pickering-Brown; Ging-Yuek R Hsiung; Caroline Lindholm; Emily Dwosh; Jennifer Gass; Ashley Cannon; Rosa Rademakers; Mike Hutton; Howard H Feldman Journal: Brain Date: 2006-11 Impact factor: 13.501
Authors: Pamela M Dean; Glenn E Smith; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Keith A Josephs Journal: J Clin Neurosci Date: 2013-09-04 Impact factor: 1.961
Authors: Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Val J Lowe; Clifford R Jack; Jennifer L Whitwell Journal: Neurology Date: 2013-06-26 Impact factor: 9.910
Authors: F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel Journal: Prog Neurobiol Date: 2011-09-03 Impact factor: 11.685
Authors: Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson Journal: Acta Neuropathol Date: 2019-01-02 Impact factor: 17.088
Authors: Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson Journal: Alzheimers Dement Date: 2019-05-02 Impact factor: 21.566